PATENT CLAIM ANALYSIS

Application Number: 16151012
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.

Claim (Index 3):
The antibody of  claim 1 , comprising the three Kabat CDRs (SEQ ID NOs: 60-62) of hSG16.17 VH3 (SEQ ID NO: 13) and three Kabat CDRs (SEQ ID NOs: 90-92) of hSG16.17 VK2 (SEQ ID NO: 19) provided that position H58 can be occupied by N or K, position H60 can be occupied by A or N, position H61 can be occupied by Q or E, position H62 can be occupied by K or N, position H64 can be occupied by Q or K, position H65 can be occupied by G or T, position L24 can be occupied by R or L, and position L53 can be occupied by S or R.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 97.0
- Lexical Diversity: 1.24
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14948183', '13990778', '15587255', '15199236', '15125570']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7333901466353892
- 35 USC 102 Novelty (BERT): 0.5425434252690089
- Combined Prediction Score: 0.7143054744987511
- Mean Citation Score: 394.93259600000016
- Max Citation Score: 407.57016
- Similarity Product: 234.9870078540229

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test